Gilead Sciences (NQ:GILD)

144.63 -0.11 (-0.08%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

78 79 Next >

Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗

April 25, 2025

Via Benzinga

Alphabet, Intel And 3 Stocks To Watch Heading Into Friday ↗

April 25, 2025

Via Benzinga

Which S&P500 stocks are moving after the closing bell on Thursday? ↗

April 24, 2025

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.

Via Chartmill

Gilead (GILD) Q1 2025 Earnings Call Transcript ↗

April 24, 2025

Via The Motley Fool

Topics Earnings World Trade

Earnings Scheduled For April 24, 2025 ↗

April 24, 2025

Via Benzinga

P/E Ratio Insights for Gilead Sciences ↗

April 23, 2025

Via Benzinga

Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance ↗

April 24, 2025

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Via Benzinga

Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates

April 24, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance...

Via StockStory

Topics Artificial Intelligence

Gilead Sciences' Bread-And-Butter Drug Missed Sales Views. And It's Not The Only One. ↗

April 24, 2025

Biktarvy sales came in below forecasts. Will Gilead stock be able to shrug it off?

Via Investor's Business Daily

Gilead Sciences Announces First Quarter 2025 Financial Results

April 24, 2025

From Gilead Sciences, Inc.

Via Business Wire

Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday? ↗

April 24, 2025

U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade...

Via Benzinga

Topics Government World Trade

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher ↗

April 24, 2025

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

Via Benzinga

Gilead Sciences's Options Frenzy: What You Need to Know ↗

April 23, 2025

Via Benzinga

Exploring Gilead Sciences's Earnings Expectations ↗

April 23, 2025

Via Benzinga

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

April 23, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Assessing Gilead Sciences: Insights From 15 Financial Analysts ↗

April 22, 2025

Via Benzinga

Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer ↗

April 21, 2025

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

Via Benzinga

Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved ↗

April 21, 2025

Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.

Via Stocktwits

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

April 21, 2025

From Gilead Sciences, Inc.

Via Business Wire

Why Quality Investors May Find GILEAD SCIENCES INC (NASDAQ:GILD) Attractive. ↗

April 19, 2025

A fundamental analysis of (NASDAQ:GILD) shows GILEAD SCIENCES INC (NASDAQ:GILD) may be suited for quality investing, we'll explore why in this article.

Via Chartmill

2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around ↗

April 17, 2025

Via The Motley Fool

Topics ETFs Economy World Trade

Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs ↗

April 16, 2025

The Time 100 list of the most influential people in the world includes Elon Musk, Mark Zuckerberg and several other CEOs of publicly traded companies.

Via Benzinga

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

3 Reasons GILD is Risky and 1 Stock to Buy Instead

April 15, 2025

In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500’s 6.9% drop. This was partly due to its solid...

Via StockStory

Topics Stocks

Is Iovance Biotherapeutics a Millionaire-Maker? ↗

April 14, 2025

Via The Motley Fool

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

April 10, 2025

From Gilead Sciences, Inc.

Via Business Wire

S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗

April 10, 2025

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Via Investor's Business Daily

Topics Government Stocks World Trade

Rule Breaker Investing: Essays From Yesterday, Vol. 7 ↗

April 10, 2025

Via The Motley Fool

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.